Medscape's AI Integration in Hematology: A Catalyst for Change at EHA 2026

Key Takeaways

• Medscape’s EHA 2026 session is titled Future-Ready Hematologists: Practical and Ethical Use of AI in Hematology and Oncology (11 June 2026, London).
• Chair Jakob N. Kather is joined by Chan Cheah and Matthew Lunning, per Medscape’s Business Wire announcement.
• Agenda topics include LLMs for guideline interpretation, hematology and oncology workflows, and ESMO ELCAP/EBAI implementation.
• FDA Oncology Center of Excellence AI work and January 2025 AI-enabled device draft guidance set the regulatory backdrop for pharma BD teams.

What is Medscape announcing for EHA 2026?

According to a Business Wire release, Medscape Education will launch the symposium at Europe’s major hematology congress.

The company frames Medscape AI as free for members and grounded in cited clinical sources. The stated goal is ethical decision support in a specialty where evidence updates move faster than any single clinician can track.

Who chairs the oncology AI session?

Prof. Jakob N. Kather of Technical University Dresden and NCT Heidelberg chairs the program. Medscape notes his role in Europe’s ESMO EBAI and ELCAP oncology AI work.

Faculty also include Prof. Chan Cheah (Sir Charles Gairdner Hospital, Perth) and Prof. Matthew Lunning (University of Nebraska Medical Center). That mix spans digital oncology methods and frontline hematology practice.

Which topics will the symposium cover?

• Large language models for guideline interpretation and treatment decisions
• Emerging AI uses in hematology and oncology clinical workflows
• Practical implementation of ESMO, EBAI, and ELCAP guidance
• Core principles of responsible AI adoption

ESMO publishes ELCAP guidance on LLMs in clinical practice and separate EBAI requirements for AI-based biomarkers. Those papers are the substance behind Medscape’s “practical and ethical” framing.

How does FDA policy frame oncology AI tools?

The FDA Oncology Center of Excellence Oncology AI Program trains reviewers and supports regulatory science on AI in cancer drug development.

In January 2025, FDA issued draft guidance on lifecycle management and marketing submissions for AI-enabled device software functions (FDA press announcement). Comment closed 7 April 2025. A related final PCCP guidance covers planned postmarket model updates.

FDA also maintains a public list of authorized AI-enabled medical devices, including hematology analyzers. That list is a market map, not an endorsement of any Medscape product.

What should pharma BD teams watch?

Prescriber AI literacy is becoming a commercial variable in hematology and broader oncology. Label claims, companion diagnostics, and real-world evidence packages will be read beside decision-support tools that summarize guidelines.

Companies in leukemia, lymphoma, and MDS should assume more clinicians will query AI systems before or during formulary debates. Early partnership with validated platforms may matter more than ad hoc chatbot demos.

Medical affairs teams should prepare short, citation-ready briefs that answer the same questions an LLM might surface: indication scope, key exclusion criteria, and where evidence is thin. If a model mis-summarizes a label, field teams need a fast correction path.

EU launch plans should also track how ELCAP-style clinician-facing tools interact with local data protection rules. Training content that travels with a product can shape how AI answers cite that brand.

What remains unproven?

A CME symposium is education, not a controlled outcome trial. Medscape’s release does not publish sensitivity, specificity, or hallucination rates for Medscape AI in hematology cases.

ESMO frameworks set expectations; they do not certify any vendor model. FDA draft device guidance is not final, and education tools may sit outside SaMD pathways entirely. Do not treat conference marketing as regulatory clearance.

No public readout from the June 11 session yet proves that AI-assisted guideline lookup improves survival, time-to-treatment, or adverse-event detection in real wards. Until peer-reviewed outcome data appear, treat the EHA program as capability-building for clinicians—not a new standard of care.

Related NovaPharma coverage

• EMA researchers map AI priorities across the medicines lifecycle
• MHRA AI sandbox for medicine safety
• EFPIA on AI across the medicines lifecycle

Frequently Asked Questions

Primary Sources

1. Business Wire — Medscape AI hematology symposium at EHA 2026
2. ESMO — ELCAP guidance on LLMs in clinical practice
3. FDA — Oncology Center of Excellence AI Program
4. FDA — Draft guidance for AI-enabled medical devices (Jan 2025)